Shots:

• AstraZeneca to receive upfront- $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & associated brands (Acimax- Antra- Mepral- Mopral- Omepral and Zoltum) excluding the US- China- Japan & Mexico
• The agreement allows AstraZeneca to focus on its three main therapeutic areas while it continues to manufacture- supply & commercialize the therapy where it holds the rights
• Losec is a proton pump inhibitor- helps to reduce the amount of acid produced by the stomach in patients with GERD & ulcers

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca